Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04750122

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro Patient-derived Tumor-like Cell Clusters for HER2 Positive Early Breast Cancer Patients

Sponsor: Peking University People's Hospital

Conditions HER2-positive Early Breast Cancer

Interventions neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning

Updated 4 times since 2021 Last updated: Mar 28, 2021 Started: Mar 28, 2021 Primary completion: Jun 30, 2022 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates HER2-positive Early Breast Cancer and is currently actively recruiting participants. Peking University People's Hospital leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2021 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Mar 2021 — May 2021 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking University People's Hospital

Data source: Peking University People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China